FDA’s Digital Health Advisory Committee Discusses Total Product Lifecycle Considerations for GenAI-Enabled Devices

While generative artificial intelligence (“GenAI”) has the potential to fundamentally change health care, it presents unique risks and complexities that challenge the U.S. Food and Drug Administration’s (“FDA” or “Agency”) historic approach to regulating medical devices….
By: Jones Day